Arcus Biosciences (NYSE:RCUS) CAO Alexander Azoy Sells 2,827 Shares of Stock

Arcus Biosciences, Inc. (NYSE:RCUS) CAO Alexander Azoy sold 2,827 shares of the business’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $30.00, for a total transaction of $84,810.00. Following the transaction, the chief accounting officer directly owned 39,581 shares of the company’s stock, valued at $1,187,430. The trade was a 6.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Alexander Azoy also recently made the following trade(s):

• On Monday, June 1st, Alexander Azoy sold 2,562 shares of Arcus Biosciences stock. The stock was sold at an average price of $25.77, for a total transaction of $66,022.74.

Arcus Biosciences Trading Down 0.5%

NYSE:RCUS opened at $30.20 on Tuesday. The company has a current ratio of 3.82, a quick ratio of 3.82 and a debt-to-equity ratio of 0.22. Arcus Biosciences, Inc. has a 12 month low of $10.07 and a 12 month high of $31.74. The company has a market cap of $3.85 billion, a PE ratio of -7.74 and a beta of 0.80. The company has a 50 day simple moving average of $28.62 and a two-hundred day simple moving average of $24.84.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.72) earnings per share for the quarter, beating the consensus estimate of ($0.89) by $0.17. The firm had revenue of $41.00 million for the quarter, compared to analysts’ expectations of $21.98 million. Arcus Biosciences had a negative return on equity of 89.54% and a negative net margin of 393.16%.The firm’s revenue was down 74.4% compared to the same quarter last year. Research analysts forecast that Arcus Biosciences, Inc. will post -3.53 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have issued reports on RCUS. Truist Financial began coverage on Arcus Biosciences in a research report on Monday, May 18th. They issued a “buy” rating and a $35.00 target price on the stock. The Goldman Sachs Group reaffirmed a “buy” rating and set a $42.00 price target on shares of Arcus Biosciences in a research report on Friday, August 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcus Biosciences in a research note on Friday, July 17th. Wall Street Zen downgraded shares of Arcus Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Lifesci Capital assumed coverage on shares of Arcus Biosciences in a research report on Thursday, June 4th. They set an “outperform” rating and a $46.00 target price for the company. Eight investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $37.80.

Institutional Trading of Arcus Biosciences

Several hedge funds have recently bought and sold shares of RCUS. Hantz Financial Services Inc. increased its position in Arcus Biosciences by 121.9% in the fourth quarter. Hantz Financial Services Inc. now owns 1,604 shares of the company’s stock worth $38,000 after buying an additional 881 shares in the last quarter. T. Rowe Price Investment Management Inc. purchased a new position in shares of Arcus Biosciences during the 4th quarter valued at about $39,000. KBC Group NV purchased a new position in shares of Arcus Biosciences during the 1st quarter valued at about $50,000. GAMMA Investing LLC grew its stake in shares of Arcus Biosciences by 10.0% during the 2nd quarter. GAMMA Investing LLC now owns 3,966 shares of the company’s stock valued at $122,000 after acquiring an additional 359 shares during the period. Finally, Nykredit A S purchased a new stake in Arcus Biosciences in the 2nd quarter worth approximately $134,000. Institutional investors own 92.89% of the company’s stock.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.